Zai Lab Receives Priority Review for Zejula’s (niraparib) NDA from NMPA (CFDA), in China

Shots:

• The priority review is granted to Zai Lab’s Zejula as a maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to Pt-based CT in adults
• The NMPA’s Priority Review is granted to the drugs to accelerate drug’s registration and approval in China for multiple thaerapy areas
• Zejula (niraparib,ZL-2306) is a qd poly (ADP-ribose) PARP1/2 inhibitor and has received FDA & EMA approval for women with recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer in Mar,2017 & Nov,2017 respectively. In Sept, 2016 Zai Lab in-licensed Zejula from Tesaro to commercialize it in China

 Click here to read full press release/ article | Ref: Zai Lab | Image:Pharma